- |||||||||| everolimus / Generic mfg.
Review, Journal: An Update on the Management of Rectal Neuroendocrine Neoplasms. (Pubmed Central) - Oct 30, 2024
Due the rarity of these tumours, much of the evidence is based on retrospective reviews or smaller cohort studies. This article is an update of the current evidence available to guide management.
- |||||||||| dexamethasone / Generic mfg., everolimus / Generic mfg.
Biomarker, Clinical, Observational data, Retrospective data, Review, Journal: Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors. (Pubmed Central) - Oct 30, 2024
The pulmonary function tests showed a mild obstructive pattern. Germline genetic testing confirmed the suspected diagnosis, and the patient started oral systemic treatment with everolimus (Afinitor) 10 mg once daily, along with dexamethasone rinses for prophylaxis.
- |||||||||| Journal, Metastases: Metastatic insulinoma-outcomes in the current era. (Pubmed Central) - Oct 30, 2024
The patients on multimodal treatments also lived a long time when considering previous published reports of median survival of just 2 years. Our findings challenge previous assumptions regarding clinical outcomes in this patient population.
- |||||||||| everolimus / Generic mfg.
Journal: Transplant Trial Watch. (Pubmed Central) - Oct 29, 2024
Close follow-up in the last 3 years showed remission without recurrence or progression. No abstract available
- |||||||||| everolimus / Generic mfg., sunitinib / Generic mfg.
Review, Journal: Gastroenteropancreatic Neuroendocrine Tumor with Peritoneal Metastasis: A Review of Current Management. (Pubmed Central) - Oct 26, 2024
Cytotoxic chemotherapy and peptide receptor radionuclide therapy may be used in select cases, though as an emerging treatment modality, the optimal sequence of peptide receptor radionuclide therapy within the existing algorithms is unknown. Significant gaps in understanding and standardized management exist, particularly for those patients presenting with peritoneal metastasis, and targeted research to optimize outcomes in this population is needed.
- |||||||||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Adverse events, Metastases: Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients. (Pubmed Central) - Oct 26, 2024
The estimated costs of managing VEGFR TKI class-effect AEs were lowest with tivozanib, and highest with lenvatinib and everolimus, indicating potentially differential healthcare resource burden by TKI regimen. The use of tivozanib in the 3
- |||||||||| prednisone / Generic mfg., everolimus / Generic mfg.
Review, Journal: Acquired Epidermodysplasia Verruciformis in a Renal Transplant Patient: Case Report and Literature Review (Pubmed Central) - Oct 25, 2024
A skin biopsy was performed that was consistent with epidermodysplasia verruciformis, so it was decided to adjust immunosuppressive therapy to everolimus, which achieved a reduction in lesions. There are only 13 other cases of acquired epidermodysplasia verruciformis in kidney transplant recipients; to our knowledge this is the first case reported in Chile.
- |||||||||| everolimus / Generic mfg.
Journal: Everolimus on cystic kidney disease burden reduction in pediatric tuberous sclerosis complex patients: a case series. (Pubmed Central) - Oct 25, 2024
There are only 13 other cases of acquired epidermodysplasia verruciformis in kidney transplant recipients; to our knowledge this is the first case reported in Chile. This report demonstrates the utility of everolimus in not only renal angiomyolipomas but also cystic kidney disease particularly in pediatric patients with a promising role in preserving renal function and preventing long term sequelae such as hematuria and hemorrhage from larger renal cysts especially if used early on in disease course.
- |||||||||| Vistide (cidofovir) / Gilead, TPOXX (tecovirimat) / SIGA Technologies
Journal: Severe Presentation of Mpox With Skin, Lung and Pleural Involvement in a Non-HIV Infected Kidney Transplant Recipient. (Pubmed Central) - Oct 23, 2024
Notwithstanding the initiation of early treatment with tecovirimat, a satisfactory response was not achieved until a reduction in immunosuppression to everolimus monotherapy, coupled with the transition to cidofovir for antiviral treatment. In conclusion, mpox has the potential to produce a severe form of systemic infection in individuals who have undergone solid organ transplantation, demanding a meticulous approach involving sequential antiviral treatment and modifications to immunosuppressive regimens in order to achieve complete healing.
- |||||||||| everolimus / Generic mfg.
Journal: Everolimus alleviates CD4+ T cell inflammation by regulating autophagy and cellular redox homeostasis. (Pubmed Central) - Oct 21, 2024
Everolimus's ability to alleviate the cytokines produced by Th17 subsets of T cells, such as IL-17A and IL-17F, was dependent on autophagy and antioxidant signaling pathways. Repurposing the antineoplastic drug everolimus for curbing inflammaging is promising, given the drug's ability to restore multiple cellular homeostasis mechanisms.
- |||||||||| everolimus / Generic mfg.
Journal: Involvement of everolimus?induced ABCB1 downregulation in drug?drug interactions. (Pubmed Central) - Oct 18, 2024
Furthermore, mRNA expression levels of ABCB1 and ABCG2 were lower in Caco/EV cells than in Caco-2 cells, and the cellular accumulation of Rhodamine 123 was significantly higher in Caco/EV cells. These findings demonstrated that continuous exposure to everolimus suppressed the expression and function of ABCB1 and ABCG2, suggesting potential drug-drug interactions via the suppression of ABCB1 and ABCG2 in the intestinal tract.
- |||||||||| Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 17, 2024
P1, N=1200, Recruiting,
These findings demonstrated that continuous exposure to everolimus suppressed the expression and function of ABCB1 and ABCG2, suggesting potential drug-drug interactions via the suppression of ABCB1 and ABCG2 in the intestinal tract. Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026
- |||||||||| giredestrant (GDC-9545) / Roche
Enrollment closed, Trial primary completion date, Metastases: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) (clinicaltrials.gov) - Oct 16, 2024
P3, N=320, Active, not recruiting,
Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2024 --> Mar 2026
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Kaposi Sarcoma in a Nonadherent Transplant Patient () - Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5436;
53-year-old Somali man with end-stage renal disease due to diabetic nephropathy underwent kidney transplant with induction with thymoglobulin, and maintained on belatacept, mycophenolate sodium (MPS), and prednisone...MPS was switched to everolimus, a mammalian target of rapamycin inhibitor (mTORi), with regression of KS skin lesions...We were able to control KS by switching to an mTORi.. . .
- |||||||||| everolimus / Generic mfg.
Review, Journal: A case report and review of rheumatoid arthritis co-occurring with tuberous sclerosis complex, a rare occurrence. (Pubmed Central) - Oct 11, 2024
We report a case of RA with TSC. The patient was a 46-year-old woman with polyarthritis and cough symptoms, rheumatoid arthritis associated interstitial lung disease (RA-ILD) was initially considered, and after more than 3 months of anti-rheumatic treatment, the patient still had cough, and further examination revealed that the patient had lymphangioleiomyomatosis in the lungs, hepatic and renal angiomyolipomas, multiple subependymal nodules, Vertebral osteosclerotic nodules, as well as facial angiofibromas and periungual fibroma, RA was finally diagnosed with TSC, and everolimus 10mg qd was added to anti-rheumatic therapy for 1 month, and the patient's cough symptoms were relieved.
- |||||||||| everolimus / Generic mfg.
Journal, Real-world evidence, Real-world, Metastases: The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study. (Pubmed Central) - Oct 10, 2024
CONCLUSION Due to the rare diagnosis and limited case reports regarding the successful use of everolimus in EAML treatment, we aim to share the favourable result achieved with everolimus. Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) and everolimus (EVE) are effective for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)...The 5y OS of patients in Group A or Group B were 62.0
- |||||||||| Clinical, Review, Journal: Interventions for BK virus infection in kidney transplant recipients. (Pubmed Central) - Oct 9, 2024
Intense monitoring early after transplantation for BK viruria and BK viraemia is effective in improving BK virus infection outcomes as it helps with early detection of the infection and allows for a timely reduction in immunosuppression reduction. There is insufficient evidence to support any other intervention for BK virus infection in kidney transplant recipients.
- |||||||||| palazestrant (OP-1250) / Olema Pharma
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus (clinicaltrials.gov) - Oct 2, 2024
P1, N=155, Recruiting,
N=140 --> 620 N=90 --> 155 | Trial completion date: Aug 2024 --> Jun 2026 | Trial primary completion date: Aug 2024 --> May 2026
- |||||||||| everolimus / Generic mfg., sirolimus / Generic mfg., cyclosporine / Generic mfg.
Journal: Toward Analytical Performance Specifications for Immunosuppressive Drug Quantification in Transplantation: An Opinion Article. (Pubmed Central) - Oct 2, 2024
However, the pCVA% values derived from the various approaches are similar and confirm that a <6% target proposed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology is adequate and realistic in combination with state-of-the-art measurement technologies. In the authors' opinion, approaches based on the width of the TR are preferable, as they represent a common basis for clinical decisions and reflect elements of biological variation and analytics used to establish the TR.
- |||||||||| tozasertib (MK-0457) / Merck (MSD), Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
TARGETED ANTI-CANCER DRUG DELIVERY IN NEUROBLASTOMA () - Oct 2, 2024 - Abstract #SIOP2024SIOP_1090;
The cytotoxic effect of DTX-?/EVER-TOZA@PEG-b-PLGA in cells significantly reduced tumor sizes in mice. Our in vitro and in vivo animal model findings support the potential of DTX-?/EVER-TOZA@PEG-b-PLGA combination as a candidate in vivo therapeutic agent for NB.
- |||||||||| Tiorfan (racecadotril) / Bioprojet
Journal: Efficacy of Racecadotril in a Patient Affected by a Therapy-Refractory VIPoma and Carcinoid Syndrome. (Pubmed Central) - Oct 1, 2024
After 5 days of treatment, the WDHA syndrome exhibited sufficient control, facilitating the patient's discharge from the ICU. This case report underscores racecadotril as an individualized, off-label treatment strategy for patients with severe VIPoma and serotonin-driven WDHA syndrome, where conventional therapeutic avenues have been exhausted.
- |||||||||| everolimus / Generic mfg.
Journal: Proton Stereotactic Body Radiotherapy for Liver Metastases From Malignant Pancreatic Insulinoma. (Pubmed Central) - Sep 30, 2024
For patients with metastatic disease, tumor control and hypoglycemic symptom relief can be achieved through surgical resection of the tumor, hepatic artery embolization, radiofrequency ablation, or radioembolization using radioactive isotopes as well as with systemic therapy such as somatostatin analogs and everolimus...Stereotactic body radiotherapy (SBRT) with protons was used to achieve symptomatic control and led to partial radiographic response with complete resolution of his hypoglycemic episodes. This case demonstrates the potential utility of proton SBRT in metastatic insulinomas.
- |||||||||| Lutathera (lutetium Lu 177 dotatate) / Novartis
Significant Improvement of Quality of Life after first dose of Peptide Receptor Radionuclide Therapy (PRRT) in a Malignant Refractory Insulinoma: a Case Report Study. (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2613;
Materials and A 62-year-old with diagnosis of metastatic malignant mixed insulinoma-gastrinoma (Ki-67 25%) and refractory hypoglycemia despite having received several lines of treatment (somatostatin analogues, everolimus, chemotherapy, liver metastasectomy and radioembolization, as well as, cyber knife for a brain metastasis)...He was proposed for PRRT with 177Lu-DOTATATE and he received the first cycle in December 2023... This case supports the rapid and significant improvement of PRRT in the control of hypoglycemia and quality of life in patients with malignant refractory insulinoma.
- |||||||||| Xalkori (crizotinib) / Pfizer, Bosulif (bosutinib) / Pfizer, Talzenna (talazoparib) / Pfizer
Drug library screens for identifying pharmaceuticals to enhance cancer response to radioligand therapy (Hall F) - Sep 27, 2024 - Abstract #EANM2024EANM_1350;
Our research has established and optimized drug library screen-based workflows suitable for identifying compounds for tumor radiosensitization and enhancing the uptake of radiolabeled ligands. This work supports and recommends further development of the screen-based discovery of novel combinatory treatments for efficacious and clinically feasible RLT in cancer.
|
